Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors

被引：0
|
作者：
S Kelly
D Wheatley
机构：
[1] Plymouth Oncology Centre,
[2] Derriford Hospital,undefined
[3] Oncology Centre,undefined
[4] Royal Cornwall Hospital,undefined
[5] Truro,undefined
[6] Cornwall TR1 3LJ,undefined
[7] UK,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
dose intensity; febrile neutropenia; G-CSF; guidelines; prophylaxis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
There is good evidence to suggest that dose intensity is important when considering the effectiveness of adjuvant chemotherapy in patients with breast cancer. However, the development of chemotherapy-induced febrile neutropenia can lead to reduction in dose intensity and other treatment modifications, which may negatively affect patient outcomes. Febrile neutropenia can be prevented by the use of primary prophylactic treatment, notably with granulocyte colony-stimulating factors. This practice is supported by international guidelines, all of which recommend that primary prophylaxis with granulocyte colony-stimulating factors should be used with chemotherapy where the risk of febrile neutropenia is 20% or greater.
引用
收藏
页码：S6 / S10
相关论文
共 50 条
  • [1] Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors
    Kelly, S.
    Wheatley, D.
    BRITISH JOURNAL OF CANCER, 2009, 101 : S6 - S10
  • [2] Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia
    Cortes de Miguel, Sol
    Angel Calleja-Hernandez, Miguel
    Menjon-Beltran, Salomon
    Vallejo-Rodriguez, Inmaculada
    SUPPORTIVE CARE IN CANCER, 2015, 23 (02) : 547 - 559
  • [3] Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia
    Sol Cortés de Miguel
    Miguel Ángel Calleja-Hernández
    Salomón Menjón-Beltrán
    Inmaculada Vallejo-Rodríguez
    Supportive Care in Cancer, 2015, 23 : 547 - 559
  • [4] Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models
    Fust, Kelly
    Parthan, Anju
    Maschio, Michael
    Gu, Qing
    Li, Xiaoyan
    Lyman, Gary H.
    Tzivelekis, Spiros
    Villa, Guillermo
    Weinstein, Milton C.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (01) : 39 - 52
  • [5] The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia
    Lyman, GH
    Kuderer, NM
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (02) : 129 - 146
  • [6] The economics of febrile neutropenia: Implications for the use of colony-stimulating factors
    Lyman, GH
    Kuderer, N
    Greene, J
    Balducci, L
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1857 - 1864
  • [7] The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia
    Jean Klastersky
    Harry Raftopoulos
    Bernardo Rapoport
    Supportive Care in Cancer, 2013, 21 : 1793 - 1795
  • [8] The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia
    Klastersky, Jean
    Raftopoulos, Harry
    Rapoport, Bernardo
    SUPPORTIVE CARE IN CANCER, 2013, 21 (06) : 1793 - 1795
  • [9] Use of a granulocyte colony-stimulating factor for the prevention of febrile neutropenia in the era of value-based care.
    Feinberg, Bruce A.
    Lord, Kevin
    Kish, Jonathan
    Laney, Jalyna R.
    Chopra, Dhruv
    Liassou, Djibril
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Supportive therapies in the prevention of chemotherapy-induced febrile neutropenia and appropriate use of granulocyte colony-stimulating factors: a Delphi consensus statement
    Adamo, Vincenzo
    Antonuzzo, Lorenzo
    Danova, Marco
    De Laurentiis, Michelino
    Marchetti, Paolo
    Pinto, Carmine
    Rosti, Giovanni
    SUPPORTIVE CARE IN CANCER, 2022, 30 (12) : 9877 - 9888
12345